Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate acute local toxicity of IORT at the dose of 20 Gy for the replacement of boost-external beam radiotherapy in Korean women who are candidates for breast-conserving treatment.
Local toxicity checklist
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intraoperative Radiotherapy | Experimental | Intervention: Intraoperative Radiotherapy * Operation day
Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity. Purse string suture pulles up tissues and wraps up the applicator. IORT with 20Gy is followed. After IORT, applicator was out of the operative field, and usual wound closure will be done. * Postoperative period
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intraoperative radiotherapy using Intrabeam® | Device | Operation day
|
| Measure | Description | Time Frame |
|---|---|---|
| Acute local toxicity in breast receiving IORT | Acute local toxicities of ipsilateral breast occurred within 6 months after IORT Local toxicity checklist
Expected number of patients with acute local toxicites associated with IORT-booster treatement is 32. Considering a drop-out rate of 10%, the trial would need to enroll 215 patients in total. | Up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Delayed local toxicity | Monitoring of local toxicity evaluated at 2 years and 5 years | Up to 5 years |
| Cosmesis | Questionnaire on cosmetic outcome of operation site Qualified assessment based on BCCT ver 2.0 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.
Patients who received prior chemotherapy or radiotherapy for breast cancer
Patients who have history of cancer other than in situ uterine cervix cancer or non-melanoma skin cancer
The depth of tumor from skin measured by ultrasonography is less than 1cm.
Contraindications to breast conservative surgery
Postoperative exclusion
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joon Jeong, M.D. Ph.D. | Gangnam Severance Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gangnam Severance Hospital | Seoul | 135720 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30467660 | Derived | Ahn SG, Bae SJ, Lee HW, Yoon CI, Kim JW, Lee IJ, Jeong J. A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients. Breast Cancer Res Treat. 2019 Feb;174(1):157-163. doi: 10.1007/s10549-018-5038-x. Epub 2018 Nov 22. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Evaluate the safety of intraoperative radiotherapy using Intrabeam in Korean patients with early breast cancer.
Not provided
Not provided
Not provided
Not provided
|
| Up to 2 years |
| Local tumor recurrence in ipsillateral breast | IBTR rate at 5 years | Up to 5 years |
| Dosimetray | -Dosimetry in tumor cavity and correlation with acute and late complication rates
| At time of surgery |
| D017437 |
| Skin and Connective Tissue Diseases |